Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
8 hedge funds and large institutions have $342M invested in Sinovac Biotech, Ltd in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 22 closing their positions.
11% less capital invested
Capital invested by funds: $383M → $342M (-$41.2M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
72% less funds holding
Funds holding: 29 → 8 (-21)
95% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 22
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$38.2M |
| 2 |
Renaissance Technologies
New York
|
-$1.54M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.04M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$179K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$106K |
SVA Hedge Fund Activity: Q4 2023 in Review
8 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2023, worth a combined $342M — down 11% from $383M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of SVA and 1 opened new positions — a net loss of 21 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Vivo Capital, exiting entirely with an estimated $38.2M sold.
- 8 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2023, down from 29 in Q3 2023.
- Funds reported $342M of Sinovac Biotech, Ltd stock for Q4 2023, down 11% quarter-over-quarter.
- 1 fund opened new Sinovac Biotech, Ltd positions in Q4 2023 and 22 closed out, a net change of -21 holders.
- The largest Sinovac Biotech, Ltd seller in Q4 2023 was Vivo Capital, an estimated $38.2M sold.
Based on aggregated 13F filings for Q4 2023.